Genmab — September 2017
-
så er der lidt musik hos mig
-
så kører vi
-
tisotumab 50% pts with activity 32% clinical respons
-
best data i past 20 years
-
næste år resultater for 6 yderligere typer cancer
-
20 years for cervical - that was
-
pivotal studies / filing på tiso - er i diskussion with regulators
-
can reach the market within the next few years
-
lugter ge valdigt af btd
-
alcyone - all data at ASH
-
surprise broadening of the label - dara+pom dex
-
massive increase in dara+pom in 2,3 and 4th line
-
new label in pom+dex will drive pom sales going forward..... holy crap¨
-
duration of treatment - already very visible
-
nævner castor pollux pfs som eksempler på lngere behandling
-
ud fra erfaringer med mono nævner jan at maintenance bliver mere og mere vigtig
-
tapdancing around "cure"
-
der er et problem med at få plads til dara patienterne i klinikkerne - håber på sc vil løse "problemet"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind